Alena Kress
A5053711551- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Virus-based gene therapy research
- interferon and immune responses
- Cancer Genomics and Diagnostics
- RNA Interference and Gene Delivery
- Pomegranate: compositions and health benefits
- Herpesvirus Infections and Treatments
- Mesenchymal stem cell research
- Bioactive Compounds in Plants
Georg Speyer Haus
2022-2024
Frankfurt Cancer Institute
2023-2024
Goethe University Frankfurt
2023-2024
T memory stem cells (TSCM) display increased self-renewal and prolonged survival capabilities, thus preventing cell exhaustion promoting effective anti-tumor responses. TSCM can be expanded by Urolithin A (UA), which is produced the commensal gut microbiome from foods rich in ellagitannins known to improve mitochondrial health. Oral UA administration tumor-bearing mice conferred strong CD8+ immunity, whereas ex vivo pre-treated displayed improved function upon adoptive transfer. UA-induced...
In colorectal cancers, the tumor microenvironment plays a key role in prognosis and therapy efficacy. Patient-derived organoids (PDTO) show enormous potential for preclinical testing; however, cultured cells lose important characteristics, including consensus molecular subtypes (CMS). To better reflect cellular heterogeneity, we established cancer organoid-stroma biobank of matched PDTOs cancer-associated fibroblasts (CAF) from 30 patients. Context-specific phenotyping showed that...
Abstract The presence of heterogeneity in responses to oncolytic virotherapy poses a barrier clinical effectiveness, as resistance this treatment can occur through the inhibition viral spread within tumor, potentially leading failures. Here we show that 4-octyl itaconate (4-OI), chemical derivative Krebs cycle-derived metabolite itaconate, enhances with VSVΔ51 various models including human and murine resistant cancer cell lines, three-dimensional (3D) patient-derived colon tumoroids...
<div>Abstract<p>In colorectal cancers (CRC) the tumor microenvironment plays a key role for prognosis and therapy efficacy. Patient-derived organoids (PDTOs) show enormous potential preclinical testing, however, cultured cells lose important characteristics including ‘consensus molecular subtypes’ (CMS). To better reflect cellular heterogeneity, we established CRC organoid-stroma biobank of matched PDTOs cancer-associated fibroblasts (CAFs) from 30 patients. Context-specific...
<p>Supplementary Figure S1 shows light microscopic images of CRC organoids and CAFs. Supplementary S2 immunostaining RNA sequencing analysis cultured S3 chromosomal copy number changes in tumors matched organoids. S4 the transcriptional variation among S5 classification cancer intrinsic subtypes (CRIS) tumors, xenotransplants. S6 tissue microarray tumor samples from colorectal organoid-stroma biobank cohort. S7 association growth characteristics with molecular features biobank. S8 CMS...
<p>Supplementary Figure S1 shows light microscopic images of CRC organoids and CAFs. Supplementary S2 immunostaining RNA sequencing analysis cultured S3 chromosomal copy number changes in tumors matched organoids. S4 the transcriptional variation among S5 classification cancer intrinsic subtypes (CRIS) tumors, xenotransplants. S6 tissue microarray tumor samples from colorectal organoid-stroma biobank cohort. S7 association growth characteristics with molecular features biobank. S8 CMS...
<title>Abstract</title> Altered metabolism and defective innate immune responses are hallmarks of tumor cells, creating a niche that can be exploited by viruses with oncolytic properties. However, heterogeneity in to virotherapy is barrier clinical effectiveness. Resistance exists occurs via inhibition viral spread within the may result treatment failures. Here we show Krebs cycle-derived metabolite itaconate its chemical derivatives or natural isomers enhance VSVΔ51M various models...
<div>Abstract<p>In colorectal cancers (CRC) the tumor microenvironment plays a key role for prognosis and therapy efficacy. Patient-derived organoids (PDTOs) show enormous potential preclinical testing, however, cultured cells lose important characteristics including ‘consensus molecular subtypes’ (CMS). To better reflect cellular heterogeneity, we established CRC organoid-stroma biobank of matched PDTOs cancer-associated fibroblasts (CAFs) from 30 patients. Context-specific...
<p>Supplementary Figure S1 shows light microscopic images of CRC organoids and CAFs. Supplementary S2 immunostaining RNA sequencing analysis cultured S3 chromosomal copy number changes in tumors matched organoids. S4 the transcriptional variation among S5 classification cancer intrinsic subtypes (CRIS) tumors, xenotransplants. S6 tissue microarray tumor samples from colorectal organoid-stroma biobank cohort. S7 association growth characteristics with molecular features biobank. S8 CMS...
<p>Supplementary Figure S1 shows light microscopic images of CRC organoids and CAFs. Supplementary S2 immunostaining RNA sequencing analysis cultured S3 chromosomal copy number changes in tumors matched organoids. S4 the transcriptional variation among S5 classification cancer intrinsic subtypes (CRIS) tumors, xenotransplants. S6 tissue microarray tumor samples from colorectal organoid-stroma biobank cohort. S7 association growth characteristics with molecular features biobank. S8 CMS...
<div>Abstract<p>In colorectal cancers, the tumor microenvironment plays a key role in prognosis and therapy efficacy. Patient-derived organoids (PDTO) show enormous potential for preclinical testing; however, cultured cells lose important characteristics, including consensus molecular subtypes (CMS). To better reflect cellular heterogeneity, we established cancer organoid–stroma biobank of matched PDTOs cancer-associated fibroblasts (CAF) from 30 patients. Context-specific...